Synpromics joined the BSGCT in Sheffield at the end of June to share the latest progress in gene and cell therapy.
On the first day, CSO Michael Roberts presented to a packed room as part of the Tools & Technologies Forum.
David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York.
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa.